Stockholm, September 6, 2023 – Vicore Pharma Holding AB (publ), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), announced today that it will present two posters on its lead program, C21, under development for the treatment of idiopathic pulmonary fibrosis (IPF), at the European Respiratory Society […]
Stockholm, August 24, 2023 – Vicore Pharma Holding AB (STO: VICO) (“Vicore”), unlocking the potential of a new class of drugs – angiotensin II type 2 receptor agonists (ATRAGs), publishes the interim report for the second quarter 2023. Important events during the second quarter In May, Vicore reported new interim 36-week data from the phase […]
Stockholm, July 13, 2023 – Vicore Pharma Holding AB (publ) (“Vicore” or the “Company”) today announced that the Board of Directors has resolved to appoint Ahmed Mousa as new CEO of the Company with start in September 2023. This follows the July 5th announcement that Carl-Johan Dalsgaard plans to retire as CEO of the Company. […]
Stockholm, 9 June 2023 – Vicore Pharma Holding AB (publ) (“Vicore” or the “Company”) has completed directed share issuances of in total 29,875,000 shares at a subscription price of SEK 16.75 per share (the “Directed Issue”), through which the Company receives SEK 500 million before transaction costs. The subscription price was determined through an accelerated […]
Stockholm, June 7, 2023 – Vicore Pharma Holding AB (STO: VICO) (“Vicore”) today announces that the European Patent Office (EPO) has granted Vicore’s patent protecting an improved C21 formulation based on enteric coated compositions. The drug candidate C21 is currently in a phase 2a trial in idiopathic pulmonary fibrosis (IPF). The European patent protection: • […]
